SAFETY AND EFFICACY OF RS 79070 ORAL GANCICLOVIR VS IV GANCICLOVIR

RS 79070 口服更昔洛韦 VS IV 更昔洛韦的安全性和有效性

• 批准号: 6275700
• 负责人: Paul R Skolnik
• 金额: $ 4.05万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275700
• 关键词: AIDS therapy; HIV infections; clinical research; cytomegalovirus; drug screening /evaluation; eye disorder chemotherapy; ganciclovir; human subject; human therapy evaluation; intravenous administration; oral administration; pharmacokinetics; prodrugs; retinitis; virus load

The objectives of this study are to investigate the safety, efficacy and pharmacokinetics of a new prodrug of oral ganciclovir, that reaches high plasma levels in comparison to the current oral formulation of ganciclovir, in patients with newly diagnosed peripheral CMV retinitis. The effects on CMV viral load will also be measured.

本研究的目的是研究安全性、有效性和 口服更昔洛韦的新前药的药代动力学，达到高 与目前的口服制剂相比， 更昔洛韦，在新诊断的外周CMV视网膜炎患者。 还将测量对CMV病毒载量的影响。